Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2163 June 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number:		Fax Number:	
Olaparib			
Prerequisites (tick boxes where appropriate) Patient has a high-grade serous* and There is documentation confirmin and Patient has newly dia and Patient has received and Patient's disease must be particular than a platinum the penultimate line** and Patient's disease must be patient's disease must be platinum the penultimate line** and Patient's disease must be platinum-based regin and	epithelial ovarian, fallopian tube, or primary peritonea g pathogenic germline BRCA1 or BRCA2 gene mutating gnosed, advanced disease one line** of previous treatment with platinum-based of thave experienced a partial or complete response to at least two lines** of previous treatment with platinum sensitive disease defined as disease progression occordination of platinum-based chemotherapy set have experienced a partial or complete response to the possibility of the previous treatment with platinum sensitive disease defined as disease progression occordination.	chemotherapy the first-line platinum-based regimen n-based chemotherapy urring at least 6 months after the last dose of	
and	hin 12 weeks of the patient's last dose of the immedia	tely preceding platinum-based regimen	
Treatment to be administered as maintenance treatment and Treatment not to be administered in combination with other chemotherapy			

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2163 June 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number:		Fax Number:	
Olaparib - continued			
Renewal — Ovarian cancer Current approval Number (if known):			
Applications only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)			
Treatment remains clinically appropriate and patient is benefitting from treatment and			
No evidence of progressive disease			
Evidence of residual (not pro	gressive) disease and the patient would continue to	benefit from treatment in the clinician's opinion	
and Treatment to be administered as maintenance treatment and			
Treatment not to be administered in combination with other chemotherapy and			
Patient has received o	ne line** of previous treatment with platinum-based o	hemotherapy	
olaparib will not be cor	ning that the patient has been informed and acknowle ntinued beyond 2 years if the patient experiences a c ce of disease at 2 years		
or Patient has received at least	two lines** of previous treatment with platinum-base	d chemotherapy	

I confirm the above details are correct and that in signing this form I understand I may be audited.

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.